Valentis Licenses Geneswitch Technology To Wyeth-Ayers

Valentis, Inc. has granted a non-exclusive license of the Company’s GeneSwitch gene regulation technology to Wyeth-Ayerst Laboratories.

The GeneSwitch system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures, aiding in the identification and characterization of a gene’s function.

Valentis is currently developing the GeneSwitch system as a component of a regulated erythropoietin gene medicine that it expects to take into human clinical testing.

The non-exclusive license is for research purposes only and consists of an up-front payment and annual maintenance fees.

No financial terms were disclosed.

Valentis maintains all rights to clinical gene therapy applications of the GeneSwitch technology.

“GeneSwitch technology will enable and enhance our efforts to mine the human genome for novel drug discovery targets,” states Dr. Charles W. Richard, Assistant Vice President of Genomics for Wyeth- Ayerst Research, the research unit of Wyeth-Ayerst.

“In deciding to license the GeneSwitch technology to pharmaceutical companies, Valentis has identified another business opportunity for its broad technology portfolio,” stated Michael P. Fons, Valentis’ Director of Business Development.

“The GeneSwitch system was initially made available to the academic research community through a license to Invitrogen. The license to Wyeth Ayerst represents the first commercial license of this technology to a major pharmaceutical company. We expect to conclude a number of similar licenses over the next year.”

Valentis, Inc. is a leader in the field of biopharmaceutical delivery.

The Company develops a broad array of products, proprietary technologies and intellectual property and applies its preclinical and early clinical development expertise to create novel therapeutics and improved versions of existing marketed biopharmaceuticals.

Purchasing Dragon Pharmaceutical of Top Quality

Trenbolone 200 - Discount Price

Administration: Injection
Active Constituent: Trenbolone Enanthate
Producer: Dragon Pharma LLC
Pack: 30 x 10 mL vial (200 mg/mL)
Price: 30 x $57.00

Clomid - Cheap Price

Administration: Oral
Basic Constituent: Clomiphene Citrate
Produced by: Dragon Pharma LLC
Amount: 20 x 100 tablets (50 mg/pastille)
Price: 20 x $58.00

TriTren 150 - Discount Price

Administration: Injection
Prime Constituent: Tri Trenbolone
Manufacturer: Dragon Pharmaceuticals
Amount: 30 x 10 mL vial (150 mg/mL)
Price: 30 x $55.00

Trenbolone 200

Injectable Anabolic Steroid
Primary Chemical Name: Trenbolone Enanthate
Manufacturer: Dragon Pharmaceutical
Amount: 1 X 10 ml (200 mg/ml)

Trenbolone 100 - Discount Price

Administration: Injection
Basic Constituent: Trenbolone Acetate
Produced by: Dragon Pharma LLC
Pack: 30 x 10 mL vial (100 mg/mL)
Price: 30 x $45.00

Enanthat 250

Injectable Steroid for Muscle Growth
Active Constituent: Testosterone Enanthate
Producer: Dragon Pharmaceutical
10 mL Sterile Multi-dose Vial (250 mg/mL)

Cut Mix 150

Injectable Steroid for Muscle Growth
Mix of: Testosterone Propionate,
Drostanolone Propionate, Trenbolone Acetate
Produced by: Dragon Pharmaceutical
10 mL Sterile Multi-dose Vial (150 mg/mL)

1-Test Cyp 200

Injectable Steroid for Muscle Growth
Main Chemical Name: Dihydroboldenone Cypionate
Produced by: Dragon Pharma LLC
10 mL Sterile Multi-dose Vial (200 mg/mL)

Cypionat 250 [10 Vials]

Injectable Steroid for Muscle Growth
Basic Component: Testosterone Cypionate
Branded by: Dragon Pharmaceuticals
10 Vials [10 mL per Vial (250 mg/ml)]
Price: 10 x $36.00 = $360.00 in Total

Parabolan 100

Basic Component: Trenbolone Hexahydrobenzylcarbonate
Producer: Dragon Pharma LLC
Pack: 10 mL vial (100 mg/mL)

Cut Mix 150

Primary Substance: Testosterone Propionate,
Drostanolone Propionate, Trenbolone Acetate
Made by: Dragon Pharma Labs
Pack: 10 x 10 mL vial (150 mg/mL)

Masteron 100

Main Substance: Drostanolone Di-Propionate
Produced by: Dragon Pharma LLC
Package: 10 x 10 mL vial (100 mg/mL)